The CD39 and CD73 ecto‐nucleotidases catabolize ATP into extracellular adenosine (eADO) [149] and in turn, eADO can inhibit anti‐tumor responses through its binding to purinergic receptors expressed on T cells [148, 150]. Here, ENTPD1 is linked to neoplasm.